Health Care & Life Sciences » Biotechnology | Green Cross Holdings Corp.

Green Cross Holdings Corp. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
80,791
101,469
112,849
74,264
70,728
19,379
Depreciation, Depletion & Amortization
20,452
26,045
31,506
35,099
41,244
47,282
Other Funds
32,465
6,550
10,075
10,248
7,038
10,038
Funds from Operations
78,963
120,152
93,031
93,309
115,370
56,623
Changes in Working Capital
61,395
65,609
85,995
94,114
29,112
15,402
Net Operating Cash Flow
17,568
54,543
7,036
805
144,482
41,221
Capital Expenditures
107,046
91,949
175,070
179,465
211,088
Sale of Fixed Assets & Businesses
249
267
234
91
200
Purchase/Sale of Investments
27,560
11,187
154,748
20,407
61,996
Net Investing Cash Flow
92,999
102,862
20,058
199,549
157,278
Cash Dividends Paid - Total
19,641
11,406
13,681
13,622
13,622
Issuance/Reduction of Debt, Net
41,394
58,142
82,427
152,607
204,746
Net Financing Cash Flow
85,877
55,344
126,321
143,770
183,549
Net Change in Cash
7,412
8,434
115,609
49,651
155,258
Free Cash Flow
82,013
23,712
144,786
160,664
30,450
Net Assets from Acquisitions
-
-
-
-
16,476
Other Sources
1,683
7
30
282
8,090
Change in Capital Stock
96,588
15,158
67,650
15,032
538
Exchange Rate Effect
3,035
1,408
2,311
6,934
15,495
Other Uses
15,445
-
-
50
-

About Green Cross Holdings

View Profile
Address
107 Ihyeon-ro 30beon-gil
Yongin GY 16924
Korea, Republic Of
Employees -
Website http://www.greencross.com
Updated 07/08/2019
Green Cross Holdings Corp. is a holding company of Green Cross Corp. that engages in the manufacture of pharmaceutical products. It establishes and coordinates business strategies for Green Cross subsidiaries that launch business and investment portfolio management. Its products include prescription drugs such as blood derivatives, cerebrovascular disease treatment, fibrinolytic agent, vaccines, hunter syndrome drug, herbal medicine, and recombinant.